{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:49:44Z","timestamp":1794980984579,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016R1A5A2012284"],"award-info":[{"award-number":["2016R1A5A2012284"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A2A1A17069277"],"award-info":[{"award-number":["2017R1A2A1A17069277"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A5A1014560"],"award-info":[{"award-number":["2017R1A5A1014560"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018M3A9H4078701"],"award-info":[{"award-number":["2018M3A9H4078701"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The low response rate of current cancer immunotherapy suggests the presence of few antigen-specific T cells and a high number of immunosuppressive factors in tumor microenvironment (TME). Here, we develop a syringeable immunomodulatory multidomain nanogel (iGel) that overcomes the limitation by reprogramming of the pro-tumoral TME to antitumoral immune niches. Local and extended release of immunomodulatory drugs from iGel deplete immunosuppressive cells, while inducing immunogenic cell death and increased immunogenicity. When iGel is applied as a local postsurgical treatment, both systemic antitumor immunity and a memory T cell response are generated, and the recurrence and metastasis of tumors to lungs and other organs are significantly inhibited. Reshaping of the TME using iGel also reverts non-responding groups to checkpoint blockade therapies into responding groups. The iGel is expected as an immunotherapeutic platform that can reshape immunosuppressive TMEs and synergize cancer immunotherapy with checkpoint therapies, with minimized systemic toxicity.<\/jats:p>","DOI":"10.1038\/s41467-019-11730-8","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T06:02:54Z","timestamp":1566280974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence"],"prefix":"10.1038","volume":"10","author":[{"given":"Chanyoung","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hathaichanok","family":"Phuengkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Vuong","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Woo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Sik","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Mo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soong Ho","family":"Um","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunseung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Soo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Mi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Heung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5558-5526","authenticated-orcid":false,"given":"Yong Taik","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"key":"11730_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","volume":"356","author":"T Takayama","year":"2000","unstructured":"Takayama, T. et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356, 802\u2013807 (2000).","journal-title":"Lancet"},{"key":"11730_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","volume":"6","author":"O Bakos","year":"2018","unstructured":"Bakos, O., Lawson, C., Rouleau, S. & Tai, L. H. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J. Immunother. Cancer 6, 86 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"11730_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"11730_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens, L. A. et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur. J. Cancer 81, 116\u2013129 (2017).","journal-title":"Eur. J. Cancer"},{"key":"11730_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"11730_CR6","doi-asserted-by":"publisher","first-page":"E415","DOI":"10.1073\/pnas.1211850110","volume":"110","author":"J Predina","year":"2013","unstructured":"Predina, J. et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc. Natl Acad. Sci. USA 110, E415\u2013E424 (2013).","journal-title":"Proc. Natl Acad. Sci. U.S.A"},{"key":"11730_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"11730_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143\u2013158 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"11730_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W Zou","year":"2005","unstructured":"Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263\u2013274 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"11730_CR10","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092\u20132099 (2015).","journal-title":"J. Clin. Oncol."},{"key":"11730_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506\u2013511 (2003).","journal-title":"Nature"},{"key":"11730_CR12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151\u20131164 (1995).","journal-title":"J. Immunol."},{"key":"11730_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/gt.2017.38","volume":"24","author":"Y Sun","year":"2017","unstructured":"Sun, Y. et al. Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation. Gene Ther. 24, 408\u2013415 (2017).","journal-title":"Gene Ther."},{"key":"11730_CR14","doi-asserted-by":"publisher","first-page":"eaak9537","DOI":"10.1126\/scitranslmed.aak9537","volume":"9","author":"JH Zheng","year":"2017","unstructured":"Zheng, J. H. et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci. Transl. Med. 9, eaak9537 (2017).","journal-title":"Sci. Transl. Med."},{"key":"11730_CR15","doi-asserted-by":"publisher","first-page":"eaar1916","DOI":"10.1126\/scitranslmed.aar1916","volume":"10","author":"CG Park","year":"2018","unstructured":"Park, C. G., Hartl, C. A. & Schmid, D. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10, eaar1916 (2018).","journal-title":"Sci. Transl. Med."},{"key":"11730_CR16","doi-asserted-by":"publisher","first-page":"e1706719","DOI":"10.1002\/adma.201706719","volume":"30","author":"H Phuengkham","year":"2018","unstructured":"Phuengkham, H., Song, C., Um, S. H. & Lim, Y. T. Implantable synthetic immune niche for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity: postoperative immunotherapy. Adv. Mater. 30, e1706719 (2018).","journal-title":"Adv. Mater."},{"key":"11730_CR17","doi-asserted-by":"publisher","first-page":"eaan3682","DOI":"10.1126\/scitranslmed.aan3682","volume":"10","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci. Transl. Med. 10, eaan3682 (2018).","journal-title":"Sci. Transl. Med."},{"key":"11730_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175\u2013196 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11730_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41551-018-0262-6","volume":"2","author":"Y Chao","year":"2018","unstructured":"Chao, Y. et al. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses. Nat. Biomed. Eng. 2, 611\u2013621 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"11730_CR20","doi-asserted-by":"publisher","first-page":"1803322","DOI":"10.1002\/adma.201803322","volume":"0","author":"H Phuengkham","year":"2019","unstructured":"Phuengkham, H., Ren, L., Shin, I. W. & Lim, Y. T. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy. Adv. Mater. 0, 1803322 (2019).","journal-title":"Adv. Mater."},{"key":"11730_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nnano.2017.113","volume":"12","author":"Y Min","year":"2017","unstructured":"Min, Y. et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol. 12, 877\u2013882 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"11730_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41565-018-0146-7","volume":"13","author":"C-S Chiang","year":"2018","unstructured":"Chiang, C. -S. et al. Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy. Nat. Nanotechnol. 13, 746\u2013754 (2018).","journal-title":"Nat. Nanotechnol."},{"key":"11730_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489\u2013496 (2017).","journal-title":"Nat. Mater."},{"key":"11730_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41563-018-0147-9","volume":"17","author":"H Wang","year":"2018","unstructured":"Wang, H. & Mooney, D. J. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat. Mater. 17, 761\u2013772 (2018).","journal-title":"Nat. Mater."},{"key":"11730_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41563-018-0028-2","volume":"17","author":"AW Li","year":"2018","unstructured":"Li, A. W. et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nat. Mater. 17, 528\u2013534 (2018).","journal-title":"Nat. Mater."},{"key":"11730_CR26","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y., Li, N., Suh, H. & Irvine, D. J. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat. Commun. 9, 022513 (2018).","journal-title":"Nat. Commun."},{"key":"11730_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature12978","volume":"507","author":"H Liu","year":"2014","unstructured":"Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519\u2013522 (2014).","journal-title":"Nature"},{"key":"11730_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01386-7","volume":"8","author":"G Zhu","year":"2017","unstructured":"Zhu, G. et al. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy. Nat. Commun. 8, 1482 (2017).","journal-title":"Nat. Commun."},{"key":"11730_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell, C. B. et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578\u2013588 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"11730_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41551-018-0254-6","volume":"2","author":"A Kulkarni","year":"2018","unstructured":"Kulkarni, A. et al. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nat. Biomed. Eng. 2, 589\u2013599 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"11730_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nnano.2016.168","volume":"11","author":"S Zanganeh","year":"2016","unstructured":"Zanganeh, S. et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11, 986\u2013994 (2016).","journal-title":"Nat. Nanotechnol."},{"key":"11730_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","volume":"14","author":"Q Chen","year":"2019","unstructured":"Chen, Q. et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat. Nanotechnol. 14, 89\u201397 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"11730_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nri.2017.89","volume":"18","author":"J Weiden","year":"2017","unstructured":"Weiden, J., Tel, J. & Figdor, C. G. Synthetic immune niches for cancer immunotherapy. Nat. Rev. Immunol. 18, 212\u2013219 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"11730_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nbt.3104","volume":"33","author":"SB Stephan","year":"2015","unstructured":"Stephan, S. B. et al. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat. Biotechnol. 33, 97\u2013101 (2015).","journal-title":"Nat. Biotechnol."},{"key":"11730_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"11730_CR36","first-page":"187","volume":"6","author":"L Bezu","year":"2015","unstructured":"Bezu, L. et al. Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol. 6, 187 (2015).","journal-title":"Front. Immunol."},{"key":"11730_CR37","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","volume":"11","author":"E Suzuki","year":"2005","unstructured":"Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. & Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+\/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713\u20136721 (2005).","journal-title":"Clin. Cancer Res."},{"key":"11730_CR38","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel, D. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125, 3356\u20133364 (2015).","journal-title":"J. Clin. Invest."},{"key":"11730_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","volume":"95","author":"SM Zeisberger","year":"2006","unstructured":"Zeisberger, S. M. et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95, 272\u2013281 (2006).","journal-title":"Br. J. Cancer"},{"key":"11730_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrd1632","volume":"4","author":"VP Torchilin","year":"2005","unstructured":"Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145\u2013160 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11730_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0163-7827(02)00004-8","volume":"41","author":"S Mantripragada","year":"2002","unstructured":"Mantripragada, S. A lipid based depot (DepoFoam\u00ae technology) for sustained release drug delivery. Prog. Lipid Res. 41, 392\u2013406 (2002).","journal-title":"Prog. Lipid Res."},{"key":"11730_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jconrel.2018.12.029","volume":"294","author":"S Manna","year":"2019","unstructured":"Manna, S. et al. Probing the mechanism of bupivacaine drug release from multivesicular liposomes. J. Control. Release 294, 279\u2013287 (2019).","journal-title":"J. Control. Release"},{"key":"11730_CR43","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/nbt.3371","volume":"33","author":"GM Lynn","year":"2015","unstructured":"Lynn, G. M., Laga, R., Darrah, P. A. & Ishizuka, A. S. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 33, 1201\u20131210 (2015).","journal-title":"Nat. Biotechnol."},{"key":"11730_CR44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fphar.2017.00304","volume":"8","author":"H Chi","year":"2017","unstructured":"Chi, H. et al. Anti-tumor activity of toll-like receptor 7 agonists. Front. Pharmacol. 8, 304 (2017).","journal-title":"Front. Pharmacol."},{"key":"11730_CR45","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/bjc.1996.569","volume":"74","author":"P Savage","year":"1996","unstructured":"Savage, P. et al. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br. J. Cancer 74, 1482\u20131486 (1996).","journal-title":"Br. J. Cancer"},{"key":"11730_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41563-018-0256-5","volume":"18","author":"DS Wilson","year":"2019","unstructured":"Wilson, D. S. et al. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. Nat. Mater. 18, 175\u2013185 (2019).","journal-title":"Nat. Mater."},{"key":"11730_CR47","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","volume":"19","author":"MF Fransen","year":"2013","unstructured":"Fransen, M. F., Van Der Sluis, T. C., Ossendorp, F., Arens, R. & Melief, C. J. M. Controlled local delivery of CTLA-4 blocking antibody induces CD8 + T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res. 19, 5381\u20135389 (2013).","journal-title":"Clin. Cancer Res."},{"key":"11730_CR48","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/2326-6066.CIR-17-0229","volume":"5","author":"S Gebremeskel","year":"2017","unstructured":"Gebremeskel, S. et al. Natural killer T-cell immunotherapy in combination with chemotherapy-induced immunogenic cell death targets metastatic breast cancer. Cancer Immunol. Res. 5, 1086\u20131097 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"11730_CR49","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","volume":"11","author":"E Suzuki","year":"2005","unstructured":"Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. & Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713\u20136721 (2005).","journal-title":"Clin. Cancer Res."},{"key":"11730_CR50","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"11730_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0022-1759(94)90012-4","volume":"174","author":"N Van Rooijen","year":"1994","unstructured":"Van Rooijen, N. & Sanders, A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174, 83\u201393 (1994).","journal-title":"J. Immunol. Methods"},{"key":"11730_CR52","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/cr.2007.81","volume":"17","author":"Y Wang","year":"2007","unstructured":"Wang, Y. et al. Rig-I-\/- mice develop colitis associated with downregulation of G alpha i2. Cell Res. 17, 858\u2013868 (2007).","journal-title":"Cell Res."},{"key":"11730_CR53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","volume":"116","author":"S Maleki Vareki","year":"2017","unstructured":"Maleki Vareki, S., Garrig\u00f3s, C. & Duran, I. Biomarkers of response to PD-1\/PD-L1 inhibition. Crit. Rev. Oncol. Hematol. 116, 116\u2013124 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"11730_CR54","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt, J. M. et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44, 1255\u20131269 (2016).","journal-title":"Immunity"},{"key":"11730_CR55","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542\u2013e551 (2016).","journal-title":"Lancet Oncol."},{"key":"11730_CR56","doi-asserted-by":"publisher","first-page":"1804490","DOI":"10.1002\/adfm.201804490","volume":"28","author":"L Ren","year":"2018","unstructured":"Ren, L. & Lim, Y. T. Degradation-regulatable architectured implantable macroporous scaffold for the spatiotemporal modulation of immunosuppressive microenvironment and enhanced combination cancer immunotherapy. Adv. Funct. Mater. 28, 1804490 (2018).","journal-title":"Adv. Funct. Mater."},{"key":"11730_CR57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nbt.3071","volume":"33","author":"J Kim","year":"2014","unstructured":"Kim, J. et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat. Biotechnol. 33, 64\u201372 (2014).","journal-title":"Nat. Biotechnol."},{"key":"11730_CR58","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3390\/ijms17111958","volume":"17","author":"GJ Szebeni","year":"2016","unstructured":"Szebeni, G. J., Vizler, C., Nagy, L. I., Kitajka, K. & Puskas, L. G. Pro-tumoral inflammatory myeloid cells as emerging therapeutic targets. Int. J. Mol. Sci. 17, 1958 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"11730_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"11730_CR60","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nnano.2015.292","volume":"11","author":"PH Lizotte","year":"2015","unstructured":"Lizotte, P. H. et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat. Nanotechnol. 11, 295\u2013303 (2015).","journal-title":"Nat. Nanotechnol."},{"key":"11730_CR61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11730_CR62","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin, U. & T\u00fcreci, \u00d6. Personalized vaccines for cancer immunotherapy. Science 359, 1355\u20131360 (2018).","journal-title":"Science"},{"key":"11730_CR63","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s00464-007-9696-8","volume":"22","author":"N Hiki","year":"2008","unstructured":"Hiki, N. et al. Laparoscopic and endoscopic cooperative surgery for gastrointestinal stromal tumor dissection. Surg. Endosc. 22, 1729\u20131735 (2008).","journal-title":"Surg. Endosc."},{"key":"11730_CR64","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrclinonc.2013.123","volume":"10","author":"AL Vahrmeijer","year":"2013","unstructured":"Vahrmeijer, A. L., Hutteman, M., van der Vorst, J. R., van de Velde, C. J. H. & Frangioni, J. V. Image-guided cancer surgery using near-infrared fluorescence. Nat. Rev. Clin. Oncol. 10, 507\u2013518 (2013).","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11730-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T04:01:07Z","timestamp":1695096067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11730-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,20]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11730"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11730-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,20]]},"assertion":[{"value":"15 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3745"}}